Centro de Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México.
Ann Hepatol. 2012 Nov-Dec;11(6):876-81.
The treatment of hepatitis C virus (HCV) genotype 1 with ribavirin (RBV) and pegylated-interferon alpha (peg-IFNα) provides a low-level sustained virological response (SVR). Single nucleotide polymorphisms (SNPs) in the interleukin 28B (IL28B) gene have been identified as SVR predictors. Our aim was to establish an association between three IL28B SNPs (rs8099917, rs12979860, and rs8103142) and the peg-IFNα/RBV treatment response in a Mexican population cohort with chronic HCV.
A cohort study was performed with 83 chronic HCV patients at the Fundación Clínica Médica Sur in Mexico City. All patients were treated with peg-IFNα and RBV. The data were analyzed by logistic regression, with adjustments for age, gender, and viral genotype, to determine any associations between the SNPs and the treatment response.
In the study group of 83 HCV patients, the main genotype was genotype 1 (70%, n = 58) and the overall SVR was 32.53% (n = 27). In the HCV-1 group, SVR was 27%, whereas SVR was 44% in the HCV-2 group. We found an association between rs12979860 CC and SVR in a codominant model (OR = 4.83, 95% CI = 1.12-20.8, P = 0.033). There was no statistically significant association between SVR and rs8099917 or rs8103142. rs12979860 polymorphisms of CC, CT, and TT, were present in 24%, 41%, and 35% of patients, respectively.
A Mexican HCV-1-infected population treated with peg-IFNα and RVB had a low SVR rate, which was associated with the SNP rs12979860 (CC). SVR was not associated with the SNPs rs8099917 or rs8103142.
使用利巴韦林 (RBV) 和聚乙二醇干扰素 α (peg-IFNα) 治疗丙型肝炎病毒 (HCV) 基因型 1 可提供低水平的持续病毒学应答 (SVR)。白细胞介素 28B (IL28B) 基因中的单核苷酸多态性 (SNP) 已被确定为 SVR 预测因子。我们的目的是在墨西哥人群队列中建立 IL28B 三个 SNP(rs8099917、rs12979860 和 rs8103142) 与 peg-IFNα/RBV 治疗反应之间的关联。
对墨西哥城 Fundación Clínica Médica Sur 的 83 名慢性 HCV 患者进行了队列研究。所有患者均接受 peg-IFNα 和 RBV 治疗。通过逻辑回归分析数据，调整年龄、性别和病毒基因型，以确定 SNP 与治疗反应之间的任何关联。
在 83 名 HCV 患者的研究组中，主要基因型为基因型 1(70%，n = 58)，总体 SVR 为 32.53%(n = 27)。在 HCV-1 组中，SVR 为 27%，而在 HCV-2 组中，SVR 为 44%。我们发现 rs12979860 CC 在共显性模型中与 SVR 相关(OR = 4.83，95%CI = 1.12-20.8，P = 0.033)。rs8099917 或 rs8103142 与 SVR 之间无统计学显著关联。CC、CT 和 TT 的 rs12979860 多态性分别存在于 24%、41%和 35%的患者中。
用 peg-IFNα 和 RVB 治疗的墨西哥 HCV-1 感染人群的 SVR 率较低，这与 SNP rs12979860 (CC) 相关。SVR 与 SNPs rs8099917 或 rs8103142 无关。
